Close Menu

NEW YORK (GenomeWeb) – 23andMe said today that it has received FDA clearance for a genetic health risk report for a syndrome associated with a higher risk of developing hereditary colorectal cancer.

The clearance enables 23andMe to report on the two most common variations in the MUTYH gene influencing MUTYH-associated polyposis (MAP), which confers a high risk for developing large numbers of pre-cancerous polyps, in turn increasing the risk for the development of CRC.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.